Abstract
Huntington’s disease arises from CAG codon-repeat expansions in the Htt gene, which leads to a Htt gene product with an expanded polyglutamine (polyQ) sequence. The length of the polyQ expansion correlates with an increased tendency to form aggregates and clustering into micrometer-plus sized inclusion bodies in neurons and other cell types. Yet after nearly 20 years since the genetic basis for HD was identified, our knowledge of how polyQ-expanded Htt fragment aggregation relates to disease mechanisms remains fragmentary and controversial. Challenges remain in defining the aggregation process at the molecular level and how this process is influenced by, or influences cellular activities. Insight is further confounded by the term “aggregation” being used to describe a composite of distinct processes that may have opposing consequences to cell health and survival. This review discusses these issues in light of a historic summary of Htt aggregation in the cellular milieu and the intrinsic attributes of polyQ-expanded Htt that lead to aggregation. Finally, discussion centers on strategies forward to improve our knowledge for how aggregation relates to cellular dysfunction.
Keywords: Huntington’s disease (HD), huntingtin, polyglutamine (polyQ), misfolding, aggregation
Current Topics in Medicinal Chemistry
Title:Putting Huntingtin “Aggregation” in View with Windows into the Cellular Milieu
Volume: 12 Issue: 22
Author(s): Danny M. Hatters
Affiliation:
Keywords: Huntington’s disease (HD), huntingtin, polyglutamine (polyQ), misfolding, aggregation
Abstract: Huntington’s disease arises from CAG codon-repeat expansions in the Htt gene, which leads to a Htt gene product with an expanded polyglutamine (polyQ) sequence. The length of the polyQ expansion correlates with an increased tendency to form aggregates and clustering into micrometer-plus sized inclusion bodies in neurons and other cell types. Yet after nearly 20 years since the genetic basis for HD was identified, our knowledge of how polyQ-expanded Htt fragment aggregation relates to disease mechanisms remains fragmentary and controversial. Challenges remain in defining the aggregation process at the molecular level and how this process is influenced by, or influences cellular activities. Insight is further confounded by the term “aggregation” being used to describe a composite of distinct processes that may have opposing consequences to cell health and survival. This review discusses these issues in light of a historic summary of Htt aggregation in the cellular milieu and the intrinsic attributes of polyQ-expanded Htt that lead to aggregation. Finally, discussion centers on strategies forward to improve our knowledge for how aggregation relates to cellular dysfunction.
Export Options
About this article
Cite this article as:
M. Hatters Danny, Putting Huntingtin “Aggregation” in View with Windows into the Cellular Milieu, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220013
DOI https://dx.doi.org/10.2174/1568026611212220013 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Heme Oxygenase-2 Protects Against Glutathione Depletion-induced Neuronal Apoptosis Mediated by Bilirubin and Cyclic GMP
Current Neurovascular Research Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes
Current Neuropharmacology Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) Acetylcholinesterase Inhibition in Alzheimers Disease
Current Pharmaceutical Design Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design